GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxcyte Inc (FRA:5VA) » Definitions » Additional Paid-In Capital

Vaxcyte (FRA:5VA) Additional Paid-In Capital : €2,760.36 Mil(As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Vaxcyte Additional Paid-In Capital?


Vaxcyte's quarterly additional paid-in capital declined from Sep. 2023 (€2,013.14 Mil) to Dec. 2023 (€1,984.92 Mil) but then increased from Dec. 2023 (€1,984.92 Mil) to Mar. 2024 (€2,760.36 Mil).

Vaxcyte's annual additional paid-in capital increased from Dec. 2021 (€515.82 Mil) to Dec. 2022 (€1,393.36 Mil) and increased from Dec. 2022 (€1,393.36 Mil) to Dec. 2023 (€1,984.92 Mil).


Vaxcyte Additional Paid-In Capital Historical Data

The historical data trend for Vaxcyte's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxcyte Additional Paid-In Capital Chart

Vaxcyte Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial 2.67 447.46 515.82 1,393.36 1,984.92

Vaxcyte Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,426.43 1,926.05 2,013.14 1,984.92 2,760.36

Vaxcyte Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Vaxcyte Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Vaxcyte's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Vaxcyte (FRA:5VA) Business Description

Industry
Traded in Other Exchanges
Address
825 Industrial Road, Suite 300, San Carlos, CA, USA, 94070
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-XP, VAX-A1, and VAX-PG.

Vaxcyte (FRA:5VA) Headlines

No Headlines